Autoimmunity BioSolutions Expands Seed Funding

Autoimmunity BioSolutions closed a $1 million seed extension, raising its total seed funding to $3.1 million.

The round was supported by Eos BioInnovation and family offices.

The new capital will help advance its personalized autoimmune therapy platform.

The company is targeting autoimmune patients who are not well served by current treatments.